欢迎使用我们的服务！
限时优惠，立即购买享受折扣
24小时客服在线，随时为您服务
优质产品，值得信赖

印度仿制药专卖店
登录
顶 置

文章列表

Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026

2026-09-26
Mirum’s Atebrioz, First Oral Approved For FOP, To Face Regeneron’s Pasatru

2026-09-26
UK To Close Regulatory Gaps With £20m Research Push

2026-09-26
Formycon Points To Benefits For Early Movers On Biosimilar Streamlining

2026-09-25
Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years

2026-09-25
Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 8-10 September 2026

2026-09-25
Lilly Adds Another China Partner With InnoCare $100m Upfront Deal

2026-09-25
Medicare Negotiation Selection Process Needs Sharper Focus On Patent Expirations

2026-09-25
Frank, in-depth discussion as Belgium and WHO map ahead priorities for collaboration

2026-09-24
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 31 August - 3 September 2026

2026-09-24
Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years

2026-09-24
Roche welcomes MHRA approval of Gazyvaro

2026-09-24